IGF-1 LR3

PEPTIDES+ MEMBERS ONLY

INDICATIONS FOR USE

IGF-1 LR3 (Insulin-like Growth Factor 1 Long Arg3) is used off-label and experimentally in the context of muscle growth, injury recovery, anti-aging, and performance enhancement. It may be prescribed in regenerative medicine to support lean muscle preservation, enhance recovery after intense training or injury, and promote cellular repair.

ROUTE OF ADMINISTRATION

  • Subcutaneous injection

  • Intramuscular injection

FORMULATIONS AND PRICING

FormulationPrice
200mcg/mL MDV (5mL)$180

COMMON INITIAL DOSING REGIMENS

  • Typical starting doses range from 20–40 mcg once daily, administered subcutaneously or intramuscularly. It is often cycled in 4–6 week blocks with rest periods between cycles to prevent desensitization.

MECHANISM OF ACTION

  • IGF-1 LR3 is a synthetic analog of IGF-1 with a modified amino acid sequence (substitution at position 3 and a 13-amino acid extension), which makes it more potent and longer-acting than native IGF-1. It binds to IGF-1 receptors on muscle and nerve tissue, activating the PI3K/Akt pathway, which promotes muscle hypertrophy, inhibits protein breakdown, and enhances glucose uptake.

  • IGF-1 also plays a role in satellite cell activation, collagen synthesis, and nerve regeneration, making it a potentially valuable tool in injury recovery and muscle repair. The “LR3” form avoids binding to IGF-binding proteins, allowing for longer duration and systemic effects.

COMMON SIDE EFFECTS

  • Metabolic: Hypoglycemia, especially if used during fasting or combined with insulin-sensitizing agents.

  • Neurologic: Headache or dizziness.

  • Musculoskeletal: Joint stiffness or localized muscle pain.

  • Injection Site: Redness, irritation, or mild swelling.

  • Rare: Water retention, tingling in extremities, or increased appetite.

CONTRAINDICATIONS

  • Absolute: Known hypersensitivity to IGF-1 or analogs. Active or recent malignancy due to its potent growth-promoting effects.

  • Relative: Use with caution in individuals with diabetes, insulin resistance, or a family history of cancer. Monitor for symptoms of hypoglycemia.

COMPARISON WITH OTHER AGENTS

  • Peptides like CJC-1295 or Sermorelin: These promote endogenous GH release and indirectly raise IGF-1 levels, whereas IGF-1 LR3 delivers more rapid and direct effects on growth pathways.

  • Testosterone: While anabolic, testosterone works through androgen receptor pathways, whereas IGF-1 LR3 works through the IGF-1 receptor. Used together, they may be synergistic.

EXPERIMENTAL TREATMENT DISCLAIMER:

  • IGF-1 LR3 is not approved by the FDA for the treatment, prevention, or mitigation of any disease. It is classified as an experimental therapy. Although promising results have been observed in laboratory and early human studies, its long-term safety and efficacy have not been established. The patient understands and accepts the experimental nature of this treatment and assumes all associated risks.

MORE INFORMATION

  • FDA Safety Data Sheet not available (experimental peptide).